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Abstract
The taurine amino-acid derivative, taurolidine, bis-(1,1-dioxoperhydro-1,2,4-thiabiazinyl–4)methane, shows broad antibac-
terial action against gram-positive and gram-negative bacteria, mycobacteria and some clinically relevant fungi. It inhibits, in
vitro, the adherence of Escherichia coli and Staphylococcus aureus to human epithelial and fibroblast cells. Taurolidine is
unstable in aqueous solution and breaks down into derivatives which are thought to be responsible for the biological
activity. To understand the taurolidine antibacterial mechanism of action, we provide the experimental single crystal X-ray
diffraction results together with theoretical methods to characterize the hydrolysis/decomposition reactions of taurolidine.
The crystal structure features two independent molecules linked through intermolecular H-bonds with one of them
somewhat positively charged. Taurolidine in a biological environment exists in equilibrium with taurultam derivatives and
this is described theoretically as a 2-step process without an energy barrier: formation of cationic taurolidine followed by a
nucleophilic attack of O(hydroxyl) on the exocyclic C(methylene). A concerted mechanism describes the further hydrolysis of
the taurolidine derivative methylol-taurultam. The interaction of methylol-taurultam with the diaminopimelic NH2 group in
the E. coli bacteria cell wall (peptidoglycan) has a negative DG value (238.2 kcal/mol) but a high energy barrier (45.8 kcal/
mol) suggesting no reactivity. On the contrary, taurolidine docking into E. coli fimbriae protein, responsible for bacteria
adhesion to the bladder epithelium, shows it has higher affinity than mannose (the natural substrate), whereas methylol-
taurultam and taurultam are less tightly bound. Since taurolidine is readily available because it is administered in high doses
after peritonitis surgery, it may successfully compete with mannose explaining its effectiveness against bacterial infections
at laparoscopic lesions.
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Introduction
Taurolidine is an anti-infective drug with a broad spectrum of
activity against gram-positive and gram-negative bacteria, anaer-
obic organisms and fungi, which is used clinically to prevent
infections after peritonitis surgery [1–2]. Jacobi [3] showed that
taurolidine is also effective in attenuating tumor spread that
normally results after laparoscopic tumor removal [4]. A model
study done with incubation of adenocarcinoma cells along with
taurolidine and/or heparin in rats showed decreased amount of
tumors in vivo and significant decrease of tumor cells in vitro; not
only was the effect of taurolidine stronger than that of heparin but,
in addition, taurolidine led to diminished E-cadherin production
[5]. More recently, the antineoplastic activity of taurolidine has
been shown against primary [6–9] and metastatic tumors [10–14].
Clinical cases include glioblastoma [14–15], gastric cancer-
recurrence [16], and ovarian cancer resistant to conventional
treatment [17]. Nevertheless, anti-infective properties of tauroli-
dine are very important. For instance, i.v. taurolidine was
successfully applied to 11 cancer patients having non-responding
microbial infections [18]. Taurolidine is effective against Staphy-
lococcus epidermidis endophthalmitis on infected rabbit’s eye [19],
infections from vancomycin-resistant Enterococcus faecalis and
methicillin-resistant Staphylococcus aureus [20]. Taurolidine also has
antiendotoxin properties as it is able to abolish the lethal effect of
toxins from E. coli in infected mice and rabbits [21–22]. Since the
mechanism of taurolidine antiadherence activity is not known, we
focus, in this study, on clarifying the molecular features responsible
for this feature.
Taurolidine mechanism of action is necessarily impacted by its
easy hydrolysis [23], Figure 1, in aqueous solution; this results in
the production of several metabolites and earlier findings
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during taurolidine hydrolysis could interact at the bacterial cell
wall [24]. E. coli, a gram-negative bacterium that colonizes the
intestinal tract and lives in symbiosis with its host is a recurrent
source of infection in humans. Over 80% of all urinary tract
infection are caused by E. coli and an overwhelming majority of
these uropathogenic isolates express filamentous organelle called
fimbriae [25]. This system provides an excellent model to study
the mechanism of action of taurolidine, since bacterium adherence
is associated with F1 fimbriae and structural features of the
proteins in pili are known. E. coli pili contain FimA (about 95%)
and the minor subunits FimF, FimG and FimH. It was found that
bacterial colonization is uniquely induced by FimH mediated
specific adhesion to a-mannoside sites which are found in many
mammalian and avian tissues. Thus, we performed docking studies
of taurolidine and its derivatives on E. coli FimH protein and
describe the results below.
The techniques we use are single crystal X-ray diffraction for
the determination of 3-D taurolidine crystal and molecular
structure, DFT theoretical calculations to study the hydrolysis/
decomposition mechanism of taurolidine and its interaction with
bacteria cell wall, and ligand-protein docking to analyze
taurolidine antiadhesion properties on E. coli FimH.
Results and Discussion
a) X-Ray Diffraction Study
Figure 2 depicts the molecular structure of the 2 independent
molecules in the asymmetric unit of taurolidine in the crystal.
These molecules differ only in rotations around certain bonds.
Table S1, deposited, shows selected geometrical features of both
taurolidine molecules in the crystal. Intermolecular H-bonds are
due to N(amine)-H --- O-S(sulfonyl). The packing shows one
molecule having more H-bonds than the other, in one molecule
they are O2 --- N62
1* (2.92 A ˚), O21 --- N42
2* (2.88 A ˚), O22 ---
N2
3* 2.99 (A ˚), N2 --- O22
3* (2.99 A ˚) and N22 --- O41
4* (3.13 A ˚),
in the other molecule they are N42 ---O21
5* (2.88 A ˚) and N62 ---
O2
6* (2.92 A ˚); n* indicates other molecular units. Since one
independent molecule has O(sulfonyl) acting as a hydrogen bond
acceptor, and the second independent molecule lacks this feature,
the former (to the right in Figure 2) has somewhat more of a
positive charge. It is interesting to note that the atoms involved in
intermolecular hydrogen bonding are the same as those forming
similar types of hydrogen bonds with amino acids in protein FimH
docking studies as will be shown later.
Taurolidine molecular structure can be compared with 2,4,7-
trimethyl-2,3-dihydro-4H-pyrido(4,3-e)-1,2,4-thiadiazinium 1,1-
dioxide iodide [26] since they share the same atoms and
connectivity in one ring. This compound has a shorter C=C
bond (1.41 A ˚), giving it a half-chair conformation, in comparison
with taurolidine’s single bond C-C (1.51-1.54 A ˚) and chair
conformations. Another closely related compound is 1,1-diox-
othiane that has S-O, S-C and C-C bond lengths quite similar to
those in taurolidine [27]. No unusual structural features are found
comparing taurolidine with other structurally related compounds
in the Cambridge crystallographic database (CSD).
b) Decomposition of Taurolidine in Biological
Environment
Taurolidine undergoes a series of hydrolysis reactions that we
study theoretically. First we analyze both independent molecules
in the crystal lattice with DFT methods using DMol3 (Cerius2)
and, as expected, find little difference of internal energy between
them (DE=0.6 kcal/mol). Using the crystal coordinates of
taurolidine the first hydrolysis (Figure 1) showed limited space
for a non hindered approach of water to cleave the exocyclic C-N
bond and, even after modifying rotational bond angles of
taurolidine to achieve more clearance, we could not find a
reaction path. Allowing the hydrolysis reaction to occur in 2 steps,
however, showed thermodynamic and kinetic feasibility. First, we
performed a H
+ attack (using [H3O]
+ or [H5O2
+]) on the N atom
that is to be cleaved from C; this process has no energy barrier and
the corresponding geometry optimized cationic taurolidine shows
one C(exocyclic)-NH2 bond (1.613 A ˚) longer than the other
C(exocyclic)-NH bond (1.408 A ˚). The 2
nd step involved a
nucleophilic attack of OH
2 on C to cleave the lengthened C-N
bond; the initial state for this reaction is depicted in Figure 3.
Next, a high temperature quantum-mechanical simulation was
performed to induce bond vibration to overcome potential energy
barriers, while the O(hydroxyl) was directed towards the exo-cyclic
C(methylene). The energy profile of the system, along with the
variation of relevant geometrical parameters is shown in Figure
S1. A potential transition state was not found. Therefore the
geometry optimized taurolidine cation and optimized hydroxyl
were placed at van der Waals distance for C and O (3.40 A ˚). The
Figure 1. Hydrolysis/decomposition of taurolidine.
doi:10.1371/journal.pone.0008927.g001
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doi:10.1371/journal.pone.0008927.g002
Figure 3. The approach of OH
2 towards cationic taurolidine. Atoms involved in a potential transition state (TS) are wireframe style; S=
yellow, N= blue, C= grey, H= white.
doi:10.1371/journal.pone.0008927.g003
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cleavage without TS, confirming the previous simulation. Figure 4
shows initial and final structures of this process. DGReaction
(2109.5 kcal/mol) indicates this reaction is therefore thermody-
namically feasible. The same result was obtained with Hartree-
Fock at 6-31-G** level of theory.
A related treatment for taurultam showed that, similar to
taurolidine, hydrolysis is not induced by a nucleophilic attack of
O(water) on C(methylene) nor from the approach of H(water) to
N. In this case, a concerted mechanism was verified performing a
linear synchronous transit search process. DMol3 Materials Studio
about the C-N cleavage was verified for water and taurultam
poised at van der Waals distance as the initial state, and methylol-
taurineamide was the cleaved product (Figure 5). The found TS
was associated with a unique imaginary frequency later confirmed
through an optimization transition state calculation (2182 cm
21).
Thermodynamic data are DGReaction of 215.1 kcal/mol and
EActivation of 15.4 kcal/mol and so this reaction is thermodynam-
ically and kinetically feasible.
We also tested the 2-step mechanism for taurultam hydrolysis to
compare with that of taurolidine. We confirmed that the first step,
attachment of H
+ on N, has no energy barrier. The 2
nd step,
nucleophilic OH
2 attack on C(methylene), was calculated at
Hartree-Fock 6–31G** level of theory and the DGReaction of
2229.4 kcal/mol indicated thermodynamic feasibility. When
performing a TS search we obtained the product, suggesting no
energy barrier. Therefore, a geometry minimization was submit-
ted but the product was not obtained; these attempts failed
because O(hydroxyl) ended up close to H atoms in CH2,N H 2 or
NH, and so this mechanism seems uncertain. Which of these 2
processes (the concerted or the 2-step hydrolysis) prevails? A
feature favoring the concerted mechanism is the much higher
Figure 4. Geometry optimization for OH
2 attack on cationic taurolidine. This is performed with DMol3 in Materials Studio: initial (left) and
final (right) states.
doi:10.1371/journal.pone.0008927.g004
Figure 5. A concerted mechanism of taurultam hydrolysis. Initial state (left), final state yielding methylol-taurineamide, (center), and the
transition state (right).
doi:10.1371/journal.pone.0008927.g005
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(55 M) compared to [H
+] and [OH
2]=10
27 M in the 2-step
mechanism. On the contrary, the TS barrier of 15 kcal/mol in the
concerted mechanism is not favored compared to no TS for the 2-
step hydrolysis, but it is achievable at room temperature. Last,
calculated DGReaction values indicate the 2-step hydrolysis is
favorable. Even though the 2-step mechanism cannot be
completely ascertained, the 2
nd hydrolysis in Figure 1 was shown
to be theoretically feasible.
c) Interaction with Peptidoglycan
The bacterial cell wall is formed by a polymeric network of
saccharide-peptide units called peptidoglycan. The penicillin
antibacterial mechanism involves peptidoglycan synthesis as it
inhibits an enzyme that builds up the cell wall. Earlier studies
suggested peptidoglycan could be a potential target for taur-
olidine as well [24]. A peptidoglycan monomer unit consists of
two joined amino sugars, N-acetylglucosamine (NAG) and N-
acetylmuramic acid (NAM), and a penta-peptide coming off of
the NAM. In E. coli, the pentapeptide is made up of L-alanine, D-
glutamic acid, meso diaminopimelic acid, and two D-alanines. In
other bacteria, lysine replaces diaminopimelic acid, with an extra
COOH.
The affinity of formaldehyde for NH2 groups of amino acids
[28] and proteins [29], through its related methylol derivatives, is
useful in vaccine production. Since taurolidine metabolism
produces formaldehyde [30], we study the potential interaction
of methylol-taurolidine derivatives with amino acids of peptido-
glycan. In particular, our interest is focused upon the action of
bacterial autolysin enzymes during the growth of the cell wall,
when the dipeptide cross-linking involving the diaminopimelic
moiety R9-(CH2)3-CHNHR0-C(O)-R90 becomes temporarily
cleaved. This results in formation of R9-(CH2)3-CHNH2C(O)-
R09 and HOR’’. The opening of the cell wall is associated with a
process needed for cell wall renovation by the arrival and
insertion of new saccharide-pentapeptide units. We hypothesize
that, as with formaldehyde, R-CH2OH methylol groups from
taurolidine will interact with the NH2 group of R9-(CH2)3-
CHNH2-C(O)-R09 to form R9-(CH2)3-CHNHCH2R-C(O)-R09;a
related model for the open peptidoglycan is shown in Figure 6. In
our quantum-mechanical study, we use a model derived from
Figure 6, namely, Pep-A and Pep-B are replaced with H atoms
and Pep-C with OH. The reaction involving this model is shown
in Figure 7.
This reaction is thermodynamically feasible for methylol-
taurultam (DG=-38.2 kcal/mol), however its transition state,
shown in Figure 8, has high activation energy (Eactivation=45.8
kcal/mol) and we conclude that, without catalysis, this reaction
most likely will not occur.
Interaction between methylol-taurineamide, shown at the
bottom of Figure 1, and an amine model did not indicate
reactivity as DG resulted positive (7.5 kcal/mol).
As mentioned above, one explanation for taurolidine’s mode of
action has been ascribed to its production of formaldehyde. Given
that formaldehyde reversibly adds water rapidly at room
temperature, there are indications of equilibrium equivalence
between formaldehyde and its hydrate, which is the simplest
methylol species. Therefore, we explored the formaldehyde
reaction with the diaminopimelic acid model and found it
thermodynamically feasible. We then analyzed the equivalence
between both reagents according to Figure 9.
At Hartree-Fock 6–31G** level of theory the formaldehyde
hydrate is more stable (DG=214.6 kcal/mol). Therefore, the
interaction of taurolidine-methylol derivatives with peptides
cannot be ascribed to an ‘‘aldehyde intermediate’’ as the latter
is less stable than the former, that is, methylol will not
transform into an aldehyde. Moreover, to convert methylol
derivatives of taurolidine to an aldehyde, a reduction reaction is
needed. From the results of all these studies, we conclude that
there is no evidence of interaction between taurolidine and
peptidoglycan.
d) Antiadhesion Properties of Taurolidine
We focus now our attention on adhesion properties of bacteria.
Taurolidine is active against E. coli [31–32], reducing adherence
of E. coli bacteria to human epithelial cells in vitro [33]. Fimbriae
proteins are considered important components in cell adhesion.
FimH is a minor component in the Fimbriae E. coli protein unit
and is crucial for E. coli infection. For instance, after directing
antibodies at the FimH amino terminal [34], or inactivating the
FimH gene cluster, E. coli lost its mannose sensitive binding
activity [35]. Moreover, by direct binding of FimH to D-mannose
attached to a carrier protein, it was demonstrated that this
protein was uniquely responsible for the receptor specificity [36].
These results extend to other enterobacteria as well, and
Figure 6. Diaminopimelic moiety in the open peptidoglycan is
shown. Pep-A stays for a D-alanine moiety, Pep-B for the D-glutamic
moiety, Pep-C represents a cross-linked peptide. We are testing whether
methylol derivatives of taurolidine (RCH2OH) attack the NH2 group to
establish a NHCH2R terminal moiety as shown in Figure 7.
doi:10.1371/journal.pone.0008927.g006
Figure 7. Theoretically studied reaction of a taurolidine-
methylol derivative RCH2OH and the pimelic NH2 group in
open peptidoglycan.
doi:10.1371/journal.pone.0008927.g007
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bacterial species [37]. In addition, a substantial homology
(.99%) of FimH among strains of animal (bovine, porcine and
avian) was observed, although avian strains had more frequent
specific mutations [38]. The role of FimH protein is to establish a
bacterial anchorage to mannoside receptors in cells for later
colonization [39]. The binding of the monosaccharide alpha-D-
mannose is the primary bladder cell receptor for uropathogenic
E. coli and this event requires a highly conserved FimH binding
pocket [40].
The FimH crystal structure with a mannose bound at the
active site on the surface of the protein [40], is shown in
Figure 10 (code 1KLF in the Protein Databank). We
superimpose the crystal structure of deoxy-mannose [41] with
each of the 4 molecules found in the unit cell of taurolidine, the
two independent molecules and their corresponding inverted
molecules. A ring of one of these taurolidine molecules shows
excellent overlap with mannose; this is also depicted in
Figure 10.
Docking of taurolidine, taurultam and methylol-taurultam at
t h ef i m b r i a ea c t i v es i t ew a sp e r f o r m e da f t e rm a n n o s ee x c l u s i o n
from the protein crystal structure using the molecular mechanics
program CDOCKER. After CHARMm force-field H generation
[42], H coordinates at the active site were made consistent with
the crystal structure [40]. Calculations for a non-zwitterionic
polypeptide showed mannose with positive binding energy,
indicating repulsion at the active site; therefore, we operated
with the zwitterionic environment corresponding to a terminal
(+)NH3 group for Phe1. Previous studies highlighted the
importance of the amine terminal group after interaction of
FimH with horseradish peroxidase, a highly mannosilated
protein, and the active site of FimH was estimated in the range
of aminoacids 1–100 [43]. For a first simulation, the active site
was kept fixed and taurolidine, taurultam and methylol-taurultam
in turn were allowed to fit. Ten poses were calculated for each
guest and the binding energy, which describes guest affinity for
the active site pocket, was calculated for each molecule’s pose.
Active site ligand minimizations, that included, in turn, all docked
molecules, were performed later. Results are shown in Table 1 for
the molecules having the best fit to the zwitterionic polypeptide; a
corresponding calculation for the mannose guest is also included.
Table 1, shows that taurolidine fits better than methylol-
taurultam or taurultam as its binding energy is the most negative,
2120.0, 296.9, and 258.6 kcal/mol, respectively. Interestingly,
the affinity of taurolidine for the protein pocket is higher than that
ofmannose. In addition, electrostatic and van derWaals energy of
mannose are repulsive (5.6 and 2.6 kcal/mol, respectively),
whereas for taurolidine they are the most negative (2103.4 and
25.6 kcal/mol respectively) in Table 1; it is clear that the affinity
of mannose for the active site of FimH is mainly due to its several
H-bonds, Figure 11. In our docking studies, one ring of
taurolidine protrudes outside the protein pocket, while for the
ring inside, the O(sulfonyl) and the NH next to it, are acceptors to
two H-bonds from the Phe1 [NH3]
+ terminal group. This
adjacent double H-bond interaction establishes a 6-membered
ring -H-N(phe1)-H-O(sulfonyl)-S-N(taur)-, the first 3 atoms from
the protein [NH3]
+ moiety, and the remaining 3 atoms from
taurolidine, Figure 12; one can assume that such cyclic
arrangement is an important stabilization factor for taurolidine
interaction with E. coli. This affinity may explain taurolidine’s
activity as an antibacterial drug after surgery, that is, the bacteria
would prefer taurolidine instead of mannose in the epithelial
tissue. The methylol-taurultam hydroxyl group forms H-bonds
with FimH Phe1, Arg46, Asp47 and Asp54, whereas the
O(sulfonyl) interacts with the [NH3]
+ terminal group: again,
there are 2 H from the [NH3]
+ terminal group acting as H-bond
donors, but they do not form a 6-membered ring as with
taurolidine; one of its H points to Asp74. Taurultam also interacts
with FimH through 4 H-bonds: the O(sulfonyl) forms H-bonds
with 2 H from the [NH3]
+ terminal group; two other H-bond
interactions are due to the NH group far from SO2;t h e ya r e
formed with Asp54 and Asn135. Therefore, the 6-membered ring
is exclusively formed by taurolidine. This arrangement is a major
factor contributing to taurolidine binding energy and consequent
affinity for FimH.
The two-step decomposition pattern of taurolidine, Figure 1,
shown earlier to stem from the H
+ attack on taurolidine, implies
that a proton transfer to the drug is needed for its hydrolysis.
Taurolidine accumulates d
+ charge as a result of its interaction
with Phe1[NH3]
+ at the active site of FimH through formation of
the double H-bond, as described above. We are investigating a
potential decomposition mechanism of taurolidine at the active site
to generate products shown in Figure 1.
Figure 8. Transition state for condensation between methylol-taurultam and a diaminopimelic acid model implying water release.
doi:10.1371/journal.pone.0008927.g008
Figure 9. Formaldehyde hydration equilibrium.
doi:10.1371/journal.pone.0008927.g009
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PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8927Figure 10. Similar structural features of taurolidine and mannose. Left: E. coli FimH protein showing a mannose guest at the active site.
Right: overlap of single crystal deoxy-mannose molecule [41] (stick display) and one of the 4 taurolidine molecules found in the unit cell. H atoms
bound to C in deoxy-mannose are omitted for clarity.
doi:10.1371/journal.pone.0008927.g010
Figure 11. Stick display of taurolidine and its derivatives, methylol taurultam and taurultam, at the active site of E. coli FimH. Top left:
taurolidinewithH-bondinteractingaminoacidsandwater(ballandspokedisplay)showstheformationofa6-memberedring-H-N(phe1)-H-O(sulfonyl)-
S-N(taur)-; the non interacting taurolidine ring protrudes outside the protein pocket. Top right: methylol taurultam shows 4 H-bonds: (a) S(sulfonyl) as a
hydrogen bond acceptor from the NH3-(Phe1), (b) O–H acts as a bifurcated hydrogen bond donor to O(carbonyl) of Arg46 and Phe1, (c) O(hydroxyl)as a
hydrogen bond acceptor from HN-(Asp47). Bottom: taurultam also has 4 hydrogen bonds: (a) O(sulfonyl) as a hydrogen bond acceptor from two
hydrogens of NH3-(Phe1), (b) N-H as hydrogen bond donor to O(carbonyl)-(Asp54) and (c) hydrogen bond acceptor from H-N-(Asn135).
doi:10.1371/journal.pone.0008927.g011
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The crystal structure of taurolidine shows two independent
molecules in the asymmetric unit with closely related internal
energy (DE=0.6 kcal/mol); this suggests taurolidine is a flexible
molecule that is capable of conformational adaptation to the
requisite geometries needed for biological activity. Crystal packing
shows one of these two molecules somewhat positively charged due
to asymmetric distribution of intermolecular H-bonds. The
hydrolysis/decomposition pattern of taurolidine is described
theoretically as a 2-step process, neither having an energy barrier.
Methylol-taurultam hydrolysis probably follows a concerted
mechanism using water as reagent. Our docking studies of binding
energies show mannose more strongly bound than taurultam and
methylol-taurultam at the active site of the protein whereas
taurolidine shows the highest affinity, associated with a stable 6-
membered ring. It is worth noting that taurolidine energy of
interaction with fimbriae is not due to extensive H-bonding, thus
making its electrostatic and van der Waals energies appear as a
strong contributor to explain its affinity for the active site, as found
by our docking results. Since taurolidine is readily available
through its administration in high doses after peritonitis surgery it
may effectively compete with mannose to avoid bacterial attack on
laparoscopic lesions. Also, docking results suggest that the role of
the hydrolysis taurolidine derivatives, taurultam and methylol-
taurultam, appears less relevant than that of the parent compound.
However, taurolidine application is also active against gram-
positive bacteria and fungi, which do not display fimbriae proteins
and, in such cases, a potential role for its hydrolysis products may
be still possible. The [NH3]
+ terminal group of Phe1 consistently
forms H-bonds with taurolidine and all its derivatives; this
effectively transfers a positive charge on taurolidine and is
reminiscent of H
+ necessary for the first step in taurolidine
decomposition as calculated in this study.
Interaction of the taurolidine derivative methylol-taurultam
with the diaminopimelic NH2 group in the bacteria cell wall has
large negative DG but high activation energy and so little evidence
for reactivity.
Figure 12. H-bond interaction of taurolidine and mannose at the FimH active site. Both molecules establish a double H-bond with NH3 of
Phe1, e.g. a 6-membered ring for taurolidine (left, ball and stick style) and a 10-membered ring for mannose (left, C-NH3 moiety of Phe1, ball and stick
style). For clarity, Phe1 is the only amino acid shown in the left figure (line style except for NH2), and only the C-NH3 moiety of Phe1 is shown for
mannose on the right.
doi:10.1371/journal.pone.0008927.g012
Table 1. Energy (kcal/mol) data for guests in the pocket of E.
coli fimbriae protein active site.
Mannose Taurolidine
Methylol-
taurultam Taurultam
Binding energy 2107.7 2120.7 296.9 258.6
Electrostatic
energy
5.6 2103.9 253.8 242.6
van der Waals
energy
2.6 25.6 20.5 22.0
doi:10.1371/journal.pone.0008927.t001
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(but so far, unknown) enzyme performance and this may induce
reactivity; this process would imply a more general mechanism of
action for taurolidine, i.e. both gram-negative and gram- positive
bacteria would be affected. Moreover, peptidoglycan forms
around 90% of the dry weight of gram-positive bacteria but
only 10% of gram-negative, and so an effective reaction of
methylol taurultam may be more significant on the gram-positive
bacteria.
Materials and Methods
The crystallographic study was performed using a Syntex-
Crystallogic diffractometer using Mo radiation. The molecular
structure was solved using direct methods [44] and refined using
CAOS [45]. The crystalline title compound was provided by
Carter-Wallace Inc. (Cranbury, NJ, USA). During data collection,
some crystal decay was observed as the intensity of three standards
([2,1,3], [1,21,3], [3,3,21]) decreased constantly and anisotrop-
ically, 217.0%, 213.0% and 23.6%, respectively, see Table 2 for
details.
The structural features, transition state and energy parameters
for taurolidine and its derivatives were analyzed with theoretical
methods using the density functional theory (DFT) program
DMol3, implemented in the packages Cerius2 4.6 (SGI platform)
and Materials Studio 4.4 (PC platform) from Accelrys [46–48].
The highest level of theory were used in these programs; in
Cerius2 the local density was the Perdew and Wang (PWC)
functional [49], in Materials Studio the local density setting was
the general gradient approximation (GGA) and the Becke
exchange (BP) functional [50]. A double numeric basis set with
polarization functions (DNP) on all atoms was set in both DMol3
programs [51]. In addition, some calculations were performed
with Hartree-Fock algorithms implemented in Spartan 06, v102
using 6–31G** basis set [52]. Taurolidine theoretical calculations
were performed using initial coordinates from the corresponding
X-ray molecular structure. All other molecules were ab-initio
generated using DMol3.
Docking studies were performed with the molecular mechanics
CDOCKER package in Discovery Studio 2.1 from Accelrys.
CDOCKER is a grid-based molecular docking method that
employs CHARMm [42]. We specified the ligand placement in
the active site using a binding site sphere of radius 10 A ˚ in the
conformer simulation for each ligand. Structures of methylol
taurultam, taurultam, and both molecules of taurolidine, stem-
ming from coordinates obtained the crystal structure, were taken
from the DFT calculations described above. They were used as
initial configurations to define 10 poses for each molecule that
were automatically placed in the active site by CDOCKER. Then,
energy calculations were performed; in this initial process the
receptor was held rigid. Several clusters of taurolidine confirmed
its flexibility, already described from the crystal structure. Later,
the binding site receptor was still held rigid while the ligands were
allowed to flex during the refinement; the resulting binding
energies along with specific van der Waals and electrostatic
energies are shown in Table 1. Binding energy is the result of
complex energy minus the addition of ligand energy plus receptor
energy. In a final calculation ligand minimization was performed
allowing the active site to be flexible, but the rest of the protein was
held fixed.
Supporting Information
Figure S1 Transition state search for taurolidine hydrolysis.
Found at: doi:10.1371/journal.pone.0008927.s001 (1.68 MB TIF)
Table S1 Experimental structural parameters of taurolidine
from the crystal.
Found at: doi:10.1371/journal.pone.0008927.s002 (0.04 MB
DOC)
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